HHLA2 member of B7 familyGenealiases: B7-H5 · B7-H7 · B7H7 · B7y
Q-omics provides the consensus-scored HHLA2 profile across patient tissues and cancer cell-line models. HHLA2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HHLA2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, HHLA2 RNA expression shows 15,369 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, and DLBC as cancer lineages where HHLA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HHLA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HHLA2 survival associations across molecular data types. HHLA2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HHLA2 RNA expression–survival associations across cancer types. High HHLA2 expression shows unfavorable associations in KICH and PAAD, but favorable associations in KIRC, KIRP, SKCM and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HHLA2 RNA expression.
This table summarizes HHLA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HHLA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HHLA2 shows lower tumor expression in COAD, KICH, LUSC and READ and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher HHLA2 RNA expression in tumor versus normal tissue (log2 FC = +3.638, t-test p < 0.001).
This table shows molecular features associated with HHLA2 in patient tissues and cancer cell lines. In patient samples, HHLA2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, HHLA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
